REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP issued a shareholder-solicitation notice reminding Regeneron investors of a securities fraud class action, with a September 14, 2026 lead-plaintiff deadline and a class period of August 1, 2025 through May 15, 2026. The complaint alleges Regeneron made false and misleading statements about the Phase III Fianlimab-Libtayo study, claiming the company used flawed statistical assumptions and failed to demonstrate clinical differentiation from other therapies.
Key figures
- Class period
- August 1, 2025 to May 15, 2026
- Class certified
- No
- Alleged statutes
- Securities Exchange Act §§10(b) and 20(a); Rule 10b-5
- Lead plaintiff deadline
- September 14, 2026
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.